The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 166:1185-a, October 2009
doi: 10.1176/appi.ajp.2009.09050700
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Google Scholar
* Articles by SOMASHEKAR, B. S.
* Articles by SHAFI, W.
PubMed
* PubMed Citation
* Articles by SOMASHEKAR, B. S.
* Articles by SHAFI, W.
Related Collections
* Bipolar Disorder
* Conventional Neuroleptics

Letter to the Editor

Maintenance Treatment for Patients With Bipolar Disorder

BETTAHALASOOR S. SOMASHEKAR, M.D., D.P.M., ASHOK KUMAR JAINER, M.D., M.R.C.Psych., and WAJID SHAFI, M.D.
Coventry, United Kingdom

To the Editor: We read the study by Dr. Suppes et al. (1) with a great deal of interest and wish to raise concerns about the methodology. The authors evaluated the efficacy and safety of the combination of quetiapine with lithium or divalproex relative to monotherapy with lithium or semisodium valproate in maintenance treatment for patients with bipolar I disorder.

Randomized controlled trials are usually cited as the gold standard for detecting the efficacy of results. However, they often can be flawed in design and are not immune to bias.

First, in this study, 1,953 patients received open-label quetiapine. However, only 628 patients were randomly allocated for maintenance treatment. This indicates that only one-third of the patients were selected for maintenance therapy, which raises the possibility of selection bias. In this regard, Healy (2) stated that company sponsored clinical trials invariably recruit samples of convenience, which by definition do not actually sustain extrapolation to normal clinical practice.

Second, the authors used a wide range of exclusion and restricted inclusion criteria, which minimized the generalizability of the results.

Finally, although both arms received active treatment, the authors failed to perform power calculation, and they did not justify the sample size, which is also a requirement of the Consolidated Standards of Reporting Trials guidelines (3).

We would appreciate clarification of these issues raised.

Footnotes

The authors report no competing interests.

This letter (doi: 10.1176/appi.ajp.2009.09050700) was accepted for publication in July 2009.

References

  1. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B: Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166:476–488[Abstract/Free Full Text]
  2. Healy D: Evidence biased psychiatry? Psychiatr Bull 2001; 25:290–291[Free Full Text]
  3. Begg C, Cho M, Eastwood S: Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637–639[Abstract/Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Google Scholar
* Articles by SOMASHEKAR, B. S.
* Articles by SHAFI, W.
PubMed
* PubMed Citation
* Articles by SOMASHEKAR, B. S.
* Articles by SHAFI, W.
Related Collections
* Bipolar Disorder
* Conventional Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org